TY - JOUR
T1 - Patient and caregiver outcomes after 6 ± 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease
T2 - The Belgian FExT study
AU - Mets, Tony
AU - Vandewoude, Maurits
AU - Jacquy, Jean
AU - Deblander, Anne
AU - MacDonald, Karen
AU - Sloesen, Anne
AU - Abraham, Ivo
PY - 2007/10/1
Y1 - 2007/10/1
N2 - Objective: Despite response variability, Cholinesterase inhibitors are recommended in mild to moderate Alzheimer's disease. Dose titration is common; however randomized controlled trials (RCTs) have mainly investigated fixed-dose regimens. We examined practice patterns and outcomes of 6 ± 1.5-month rivastigmine therapy. Methods: Prospective, pharmacoepidemiologic, naturalistic study of 175 evaluable patients with mild to moderate Alzheimer's disease (+ 151 caregivers) from 52 centers in Belgium on 6 ± 1.5 month (titrated) rivastigmine treatment. Main outcome measures: Measured at baseline (enrollment) and follow-up (6 ± 1.5 months). For patients: Mini-Mental State Exam (MMSE), Activities of Daily Living (ADL), Neuropsychiatric Inventory (NPI), Global Deterioration Scale (GDS) scores; treatment response (improvement, maintenance, or decline less than normative slope). For caregivers: hours/week spent caring; Zarit Caregiver Burden Scale (ZCBS), 12-item version of General Health Questionnaire (GHQ-12), Instrumental Activities of Daily Living (IADL) scores.
AB - Objective: Despite response variability, Cholinesterase inhibitors are recommended in mild to moderate Alzheimer's disease. Dose titration is common; however randomized controlled trials (RCTs) have mainly investigated fixed-dose regimens. We examined practice patterns and outcomes of 6 ± 1.5-month rivastigmine therapy. Methods: Prospective, pharmacoepidemiologic, naturalistic study of 175 evaluable patients with mild to moderate Alzheimer's disease (+ 151 caregivers) from 52 centers in Belgium on 6 ± 1.5 month (titrated) rivastigmine treatment. Main outcome measures: Measured at baseline (enrollment) and follow-up (6 ± 1.5 months). For patients: Mini-Mental State Exam (MMSE), Activities of Daily Living (ADL), Neuropsychiatric Inventory (NPI), Global Deterioration Scale (GDS) scores; treatment response (improvement, maintenance, or decline less than normative slope). For caregivers: hours/week spent caring; Zarit Caregiver Burden Scale (ZCBS), 12-item version of General Health Questionnaire (GHQ-12), Instrumental Activities of Daily Living (IADL) scores.
KW - Alzheimer's disease
KW - Evidence-based medicine
KW - Outcomes research
KW - Pharmacoepidemiology
KW - Rivastigmine
KW - Treatment effectiveness
UR - http://www.scopus.com/inward/record.url?scp=35648935963&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35648935963&partnerID=8YFLogxK
U2 - 10.1185/030079907X226375
DO - 10.1185/030079907X226375
M3 - Article
C2 - 17784995
AN - SCOPUS:35648935963
VL - 23
SP - 2485
EP - 2501
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
IS - 10
ER -